JP2023521604A5 - - Google Patents
Info
- Publication number
- JP2023521604A5 JP2023521604A5 JP2022559557A JP2022559557A JP2023521604A5 JP 2023521604 A5 JP2023521604 A5 JP 2023521604A5 JP 2022559557 A JP2022559557 A JP 2022559557A JP 2022559557 A JP2022559557 A JP 2022559557A JP 2023521604 A5 JP2023521604 A5 JP 2023521604A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002030P | 2020-03-30 | 2020-03-30 | |
| US63/002,030 | 2020-03-30 | ||
| US202163164467P | 2021-03-22 | 2021-03-22 | |
| US63/164,467 | 2021-03-22 | ||
| PCT/US2021/024858 WO2021202511A2 (en) | 2020-03-30 | 2021-03-30 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521604A JP2023521604A (ja) | 2023-05-25 |
| JP2023521604A5 true JP2023521604A5 (https=) | 2024-04-10 |
| JPWO2021202511A5 JPWO2021202511A5 (https=) | 2024-04-10 |
Family
ID=77929772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559557A Pending JP2023521604A (ja) | 2020-03-30 | 2021-03-30 | 微小管関連タンパク質タウ（ＭＡＰＴ）ｉＲＮＡ剤組成物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230203486A1 (https=) |
| EP (1) | EP4126230A4 (https=) |
| JP (1) | JP2023521604A (https=) |
| KR (1) | KR20230005194A (https=) |
| CN (1) | CN116234585A (https=) |
| AU (1) | AU2021246024A1 (https=) |
| BR (1) | BR112022019606A2 (https=) |
| CA (1) | CA3178304A1 (https=) |
| IL (1) | IL296851A (https=) |
| MX (1) | MX2022012293A (https=) |
| TW (1) | TW202143984A (https=) |
| WO (1) | WO2021202511A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240067943A (ko) * | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| US20250340872A1 (en) * | 2021-10-07 | 2025-11-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing tau expression |
| EP4448765A1 (en) * | 2021-12-13 | 2024-10-23 | Eli Lilly and Company | Mapt rna interference agents |
| JP2025507372A (ja) * | 2022-02-11 | 2025-03-18 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 微小管関連タンパク質タウ（ＭＡＰＴ）ｉＲＮＡ剤組成物およびその使用方法 |
| EP4493691A2 (en) * | 2022-03-16 | 2025-01-22 | JANSSEN Pharmaceutica NV | Mapt sirna and uses thereof |
| KR20250129743A (ko) * | 2022-12-29 | 2025-08-29 | 보이저 테라퓨틱스, 인크. | Mapt를 조절하기 위한 조성물 및 방법 |
| WO2024201423A2 (en) * | 2023-03-30 | 2024-10-03 | Biorchestra Co., Ltd. | Microtubule-associated protein tau targeting sirnas and uses thereof |
| WO2024220930A2 (en) * | 2023-04-20 | 2024-10-24 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| AU2024315297A1 (en) * | 2023-08-01 | 2026-02-12 | Tuojie Biotech (Shanghai) Co., Ltd. | Dsrna targeting mapt and pharmaceutical use thereof |
| WO2025027577A1 (en) * | 2023-08-02 | 2025-02-06 | Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) | Micrornas designed against the microtubule-associated protein tau for the treatment of tauopathies |
| TW202515584A (zh) * | 2023-10-11 | 2025-04-16 | 大陸商上海舶望製藥有限公司 | 用於抑制微管相關蛋白ｔａｕ（ｍａｐｔ）表達的組合物和方法 |
| US12551569B2 (en) | 2024-03-31 | 2026-02-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use |
| WO2025233849A2 (en) * | 2024-05-07 | 2025-11-13 | Janssen Pharmaceutica Nv | MAPT siRNA AND USES THEREOF |
| WO2026010722A1 (en) * | 2024-07-03 | 2026-01-08 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2026017176A1 (zh) * | 2024-07-19 | 2026-01-22 | 北京安龙生物医药有限公司 | 靶向微管相关蛋白Tau基因的寡核苷酸及其用途 |
| CN121780524A (zh) * | 2024-08-02 | 2026-04-03 | 北京尧景基因技术有限公司 | 抑制MAPT基因表达的siRNA及其缀合物和应用 |
| WO2026067655A1 (zh) * | 2024-09-26 | 2026-04-02 | 大睿生物医药科技(上海)有限公司 | 调控TAU表达的dsRNA分子 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| GB0605337D0 (en) * | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| AU2013203395A1 (en) * | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
| US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| ES2807379T3 (es) * | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
| JP2016523980A (ja) * | 2013-07-11 | 2016-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | タウ発現を抑制するマイクロｒｎａ |
| TWI772856B (zh) * | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| EP3043826A4 (en) * | 2013-09-13 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| AU2016215155A1 (en) * | 2015-02-04 | 2017-08-17 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| EP3274456B1 (en) * | 2015-03-25 | 2020-06-24 | Università Degli Studi Di Trento | Rna interference mediated therapy for neurodegenerative diseases |
| CN108135921B (zh) * | 2015-07-22 | 2023-10-17 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| PH12018501207B1 (en) * | 2015-12-21 | 2024-02-23 | Novartis Ag | Compositions and methods for decreasing tau expression |
| CA3086485A1 (en) * | 2017-12-21 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded rna agents |
| SG11202012759XA (en) * | 2018-07-03 | 2021-01-28 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
| WO2021156833A1 (en) * | 2020-02-07 | 2021-08-12 | Biorchestra Co., Ltd. | Use of mirna-485 inhibitors for treating tauopathy |
| AU2021238319A1 (en) * | 2020-03-18 | 2022-10-06 | University Of Massachusetts | Oligonucleotides for MAPT modulation |
-
2021
- 2021-03-30 AU AU2021246024A patent/AU2021246024A1/en active Pending
- 2021-03-30 TW TW110111671A patent/TW202143984A/zh unknown
- 2021-03-30 WO PCT/US2021/024858 patent/WO2021202511A2/en not_active Ceased
- 2021-03-30 IL IL296851A patent/IL296851A/en unknown
- 2021-03-30 EP EP21779121.9A patent/EP4126230A4/en active Pending
- 2021-03-30 KR KR1020227037984A patent/KR20230005194A/ko active Pending
- 2021-03-30 JP JP2022559557A patent/JP2023521604A/ja active Pending
- 2021-03-30 MX MX2022012293A patent/MX2022012293A/es unknown
- 2021-03-30 US US17/995,035 patent/US20230203486A1/en active Pending
- 2021-03-30 CA CA3178304A patent/CA3178304A1/en active Pending
- 2021-03-30 BR BR112022019606A patent/BR112022019606A2/pt unknown
- 2021-03-30 CN CN202180039190.6A patent/CN116234585A/zh active Pending